We believe that measures of operating performance which exclude these impacts are

We believe that measures of operating performance which exclude these impacts are helpful in analyzing our results. We also believe that an increasing EBITDA and Adjusted EBITDA depicts increased ability to attract financing and increases the valuation of our business. We do not consider EBITDA and Adjusted EBITDA to be a measure of cash flow, as they do not consider certain cash requirements such as interest, income taxes or debt service payments. We do not consider EBITDA or Adjusted EBITDA to be a substitute for operating income or net income. Instead, we believe that EBITDA and Adjusted EBITDA are useful performance measures which should be considered in addition to GAAP performance measures.

(1)Operating income (loss) includes the following restructuring and related costs and asset impairment charges: Quarter Ended March 31,2009 2008---- ---- Small BusinessServices $27.3($0.2) FinancialServices 0.1 (0.3) Direct Checks(0.1) - Total $27.3($0.5)The table below is provided to assist in understanding the comparability ofthe Company's results of operations for the quarters ended March 31, 2009 and2008.The Company's management believes that operating income by segment,excluding the restructuring and related costs and asset impairment charges ineach period, is a useful non-GAAP financial measure because the unusual itemsduring 2009 and 2008 impacted the comparability of reported operating income. The presentation below is not intended as an alternative to results reportedin accordance with generally accepted accounting principles (GAAP) in theUnited States of America. Instead, the Company believes that this informationis a useful financial measure to be considered in addition to GAAP performancemeasures. DELUXE CORPORATIONSEGMENT OPERATING INCOMEEXCLUDING RESTRUCTURING AND RELATED COSTS AND ASSET IMPAIRMENT CHARGES(In millions) Quarter Ended March 31,20092008--------Adjusted operating income: (1) Small BusinessServices $20.7 $21.6 Financial Services 19.718.7 Direct Checks14.114.7 Total $54.5 $55.0(1)Operating income excluding restructuring and related costs and asset impairment charges reconciles to reported operating income as follows: Quarter Ended March 31,2009 2008---- ----Adjusted operating income$54.5$55.0Restructuring and related costs and asset impairment charges: Small BusinessServices (27.3) 0.2 FinancialServices(0.1) 0.3 Direct Checks 0.1- Total (27.3) 0.5Reported operating income$27.2$55.5 SOURCEDeluxe Corp.Terry D.

Peterson, VP, Investor Relations and Chief Accounting Officer ofDeluxe Corporation, +1-651-787-1068. CyberKnife Radiosurgery Used to Treat More Than 3,000 Prostate Cancer PatientsWorldwideAccuray to Present CyberKnife Capabilities at Leading Urology Annual MeetingSUNNYVALE, Calif., April 23 /PRNewswire-FirstCall/ -- Accuray Incorporated(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced todaythat more than 3,000 prostate cancer patients have been treated to dateworldwide using the CyberKnife(R) Robotic Radiosurgery System. In fact, in thethird quarter of Accuray's fiscal year, approximately 400 prostate cancerpatients were treated. The company will be presenting the unique capabilitiesof the CyberKnife System at this year's American Urological Association (AUA)Annual Meeting, April 25-30 in Chicago, Illinois.On Sunday, April 26 from 3:00 p.m.-4:00 p.m.

CDT, CyberKnife radiosurgery willbe featured as part of the AUA's Industry Clinical Update Theater, whichoffers a variety of educational talks and presentations during the AnnualMeeting. Lee Ponsky, M.D., chief of the Division of Urologic Oncology,University Hospitals Case Medical Center in Cleveland, Ohio; and DavidSpellberg, M.D., Urologist, Naples Urology Associates in Naples, Florida, willpresent a technical, clinical and business overview of the CyberKnife System,as well as their experience to date treating prostate cancer. The IndustryClinical Update Theater is centrally located at McCormick Place within theScience and Technology Hall. Considerable interest in CyberKnife radiosurgery is expected at this year'smeeting, following last month's publication of clinical results from aprospective study of CyberKnife radiosurgery for prostate cancer thatdemonstrated 100 percent PSA response at 33 months. Using pinpointaccuracy to deliver high doses of radiation to moving targets such as theprostate, CyberKnife radiosurgery is typically complete in five or fewer briefoutpatient visits. Other radiation delivery techniques typically require 40daily treatments that can amount to a two month treatment regimen.